C. Ola Landgren, M.D., Ph.D. (IMAGE)

University of Miami Miller School of Medicine

C. Ola Landgren, M.D., Ph.D.

Caption

Over the last decade, multiple myeloma treatment options have evolved from double, to triple to quadruple combination therapies. What do these new options mean for patients, and how will treatment change in the future? C. Ola Landgren, M.D., Ph.D., will address these questions and more June 3, at the 2024 annual meeting of the American Society of Clinical Oncology (ASCO).

Credit

Photo by Sylvester

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.